The National Health Surveillance Agency (Anvisa) unanimously authorized, this Thursday (20), the use of the Coronavac vaccine in the age group of 6 to 17 years, with the exception of immunosuppressed children and adolescents.
“It is very important that we have one more vaccine for children”, evaluated immunologist and professor of Medicine at the University of São Paulo (USP) Jorge Kalil, in an interview with CNN.
The expert pointed out that, although the vaccine has a lower level of protection for the elderly and immunosuppressed people, the immunizer has shown good results in children.
Although the Butantan Institute has asked Anvisa for authorization for the use of Coronavac in children from the age of three, at the moment the agency only approved the vaccine from the age of six.
“Without a doubt, Anvisa did it as a precaution, until it had data”, pondered the immunologist. He also added that the agency “is fulfilling its role, which is to provide security for us Brazilians and for our children and grandchildren”.
* Under supervision of Elis Franco and Rafaela Lara
Reference: CNN Brasil
